TABLE 1

Comparison of demographic characteristics of patients with S. maltophilia infection who received monotherapy with FQ or SXT

Patient characteristicValueaP valuec
Overall (n = 98)FQ (n = 63)SXT (n = 35)
Levofloxacin (n = 48)Ciprofloxacin (n = 15)P valuebTotal (n = 63)
Male gender60 (61)31 (65)8 (53)0.4339 (62)21 (60)0.85
Age (yr) (mean ± SD)73 ± 1569 ± 1471 ± 180.6369 ± 1573 ± 150.12
Underlying illness
    Major surgery42 (43)21 (44)7 (47)0.8428 (44)14 (40)0.67
    Malignancy (Solid Organ)38 (39)21 (44)3 (20)0.1024 (38)14 (40)0.85
    Coronary artery disease37 (38)19 (40)7 (47)0.6326 (41)11 (31)0.34
    Diabetes mellitus35 (36)19 (40)7 (47)0.6326 (41)9 (26)0.12
    Chronic kidney diseases/hemodialysis25 (26)14 (29)4 (27)1.016 (25)9 (26)0.97
    Pulmonary disease25 (26)14 (29)4 (27)1.018 (29)7 (20)0.35
    Congestive heart failure24 (25)13 (27)6 (40)0.3519 (30)5 (14)0.08
    Liver disease9 (9)4 (8)3 (20)0.347 (11)2 (6)0.38
    Malignancy (hematological)4 (4)3 (6)0 (0)1.03 (5)1 (3)0.65
Immunosuppression
    Chemotherapy19 (19)11 (23)1 (7)0.2612 (19)7 (20)0.91
    Prednisone ≥ 20 mg/day9 (9)5 (10)0 (0)0.335 (8)4 (11)0.57
    Solid organ/stem cell transplant5 (6)2 (4)2 (13)0.243 (6)2 (7)0.81
    Neutropeniad6 (6)4 (8)1 (7)1.05 (8)1 (3)0.32
    Tacrolimus or mycophenolate mofetil5 (5)2 (8)2 (13)0.244 (6)1 (3)0.45
Indwelling devices
    Genitourinary catheter33 (34)19 (40)4 (27)0.36423 (37)10 (29)0.43
    Mechanical ventilation29 (30)15 (31)2 (13)0.31717 (27)12 (34)0.45
    Central venous catheter14 (14)8 (17)1 (7)0.679 (14)5 (14)1.00
    Intra-abdominal drain7 (7)1 (2)0 (0)1.01 (2)6 (17)<0.01
    Chest tube4 (4)2 (4)0 (0)1.02 (3)2 (6)0.54
    Ventriculoperitoneal shunt4 (4)1 (2)1 (7)0.4222 (3)2 (6)0.54
Prior antibiotic use82 (84)44 (92)10 (67)0.0354 (86)28 (80)0.46
    Cephalosporins48 (49)31 (65)5 (33)0.0336 (57)12 (34)0.03
    Ceftazidime1 (2)1 (3)0 (0)1.01 (3)01.0
    Penicillins47 (48)22 (46)7 (47)0.9629 (46)18 (51)0.61
    Carbapenems29 (30)16 (33)3 (20)0.5219 (30)10 (29)0.87
    Aminoglycosides17 (17)11 (23)3 (20)1.014 (22)3 (9)0.09
    Fluoroquinolones17 (17)7 (15)2 (13)1.09 (14)8 (23)0.28
        Levofloxacin7 (41)2 (29)0 (0)1.02 (22)5 (63)0.04
        Ciprofloxacin7 (41)4 (57)2 (100)0.6226 (67)1 (13)0.22
        Moxifloxacin3 (18)1 (2)0 (0)1.01 (11)2 (25)0.85
    Tigecycline6 (6)4 (8)1 (7)1.05 (8)1 (3)0.42
    Trimethoprim-sulfamethoxazole5 (5)3 (6)1 (7)1.04 (6)1 (3)0.65
Site of infection
    Pulmonary55 (56)32 (67)6 (40)0.0738 (60)17 (49)0.26
    Skin/skin structure19 (19)5 (10)4 (27)0.209 (14)10 (29)0.09
    Urine9 (9)5 (10)2 (13)0.676 (10)3 (9)1.0
    Intra-abdominal9 (9)2 (4)3 (20)0.085 (8)4 (11)0.72
    Bacteremia6 (6)4 (8)1 (7)1.05 (8)1 (3)0.42
        CRBSIe3 (50)2 (50)1 (100)0.563 (60)00.55
        Pulmonary2 (33)1 (25)0 (0)1.01 (20)1 (100)1.0
        Skin/skin structure1 (17)1 (25)0 (0)1.01 (20)01.0
Polymicrobial infection75 (77)31 (65)12 (80)0.3553 (84)22 (63)0.02
    Gram-negative organism38 (39)21 (44)8 (53)0.5229 (46)9 (26)0.04
        Pseudomonas spp.10 (26)5 (24)3 (38)0.388 (28)2 (22)0.49
        Escherichia coli5 (13)4 (19)1 (13)1.05 (17)00.09
        Enterobacter spp.7 (18)5 (24)1 (13)1.06 (21)1 (11)0.42
        Serratia spp.3 (8)1 (5)0 (0)1.01 (3)2 (22)0.29
        Proteus spp.3 (8)0 (0)1 (13)0.241 (3)2 (22)0.29
        Klebsiella spp.8 (21)5 (24)1 (13)1.06 (21)2 (22)0.71
        Acinetobacter spp.7 (18)4 (19)2 (25)0.626 (21)1 (11)0.42
        Gram-positive organism38 (39)18 (38)7 (47)0.5325 (40)13 (37)0.81
        Enterococcus spp.15 (39)8 (44)2 (29)1.010 (40)5 (38)0.83
        Methicillin-resistant Staphylococcus aureus15 (39)9 (50)2 (29)1.011 (44)4 (31)0.43
        Methicillin-resistant Staphylococcus epidermidis7 (18)2 (11)2 (29)0.564 (10)3 (23)0.68
        Methicillin-sensitive S. aureus6 (16)3 (17)1 (14)1.03 (12)3 (23)0.45
LOSf prior to culture (days) [median (IQR)]5 (1–15)6.5 (0–68)3 (0–136)0.766 (1–19)4 (0–11)0.79
LOS (days) [median (IQR)]22 (12–38)26.5 (4–149)21 (5–166)0.3725 (15–37)16 (8–42)0.97
Days to treatment (days) [median (IQR)]3 (2–4)3 (0–36)2 (0–14)0.103 (2–4)3 (2–5)0.98
ICU admission at time of culture23 (24)16 (33)1 (7)0.0517 (27)6 (17)0.27
CPISg [median (IQR)]4 (3–6)4 (1–8)3 (1–6)0.164 (3–6)4 (3–7)0.89
CCIh [median (IQR)]7 (5–8)7 (0–13)6 (1–9)0.614)7 (5–8)7 (4–8)0.90
  • a All values shown as number (percent), unless otherwise specified.

  • b P value comparing patients who received levofloxacin to patients who received ciprofloxacin.

  • c P value comparing patients who received trimethoprim-sulfamethoxazole to patients who received a fluoroquinolone.

  • d Defined as an absolute neutrophil count below 500 cells/mm3.

  • e CRBSI, catheter-related bloodstream infection.

  • f LOS, length of stay.

  • g CPIS, clinical pulmonary infection score; only calculated for pulmonary infections.

  • h CCI, Charlson comorbidity index.